AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS lobbying for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 17, 2025

Expenses

$220,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Maryland

Official filing document

Government bodies contacted 8

Centers For Medicare and Medicaid Services (CMS)
Drug Enforcement Administration (DEA)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
Health Resources & Services Administration (HRSA)
HOUSE OF REPRESENTATIVES
SENATE
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 929
Dr. Lorna Breen Health Care Provider Protection Reauthorization Act
S 266
Dr. Lorna Breen Health Care Provider Protection Reauthorization Act
S 5397
Rebuild America’s Health Care Schools Act of 2024
HR 10225
Rebuild America’s Health Care Schools Act of 2024

Lobbying activity 3

Health Issues

Issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain (generally, no specific legislation). Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). Provisions related to site neutral payments (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation).

Medicare/Medicaid

The Equitable Community Access to Pharmacist Services Act, including reimbursement for pharmacist provision of testing and vaccination. Issues related to telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS (generally, no specific legislation).

Pharmacy

Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). Issues related to 340B program nondiscrimination and contract pharmacy arrangements (generally, no specific legislation). Issues related to manufacturer attempts to undercut the 340B program (generally, no specific legislation). Issues related to pharmacy residency funding, including support for the Rebuild Americas Health Care Schools Act of 2024 (S. 5397/H.R. 10225). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation).